Skip to main content
SpringerLink
Log in

Tafamidis: A Review in Transthyretin Amyloidosis with Polyneuropathy

  • Adis Drug Evaluation
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Transthyretin amyloidosis with polyneuropathy (ATTR-PN), a rare and progressive hereditary disorder, results from mutations in the gene coding for the transthyretin (TTR) protein that destabilize the protein’s tetrameric structure. In over 40 countries worldwide, tafamidis (Vyndaqel®) is approved for the treatment of TTR amyloidosis in adults with stage 1 symptomatic polyneuropathy, to delay peripheral neurological impairment. Tafamidis is administered orally once daily, as a soft capsule. Evidence from clinical studies, including an 18-month placebo-controlled trial and subsequent long-term, open-label extension studies (providing data from ≤ 6 years of treatment), indicate that tafamidis slowed deterioration of neurological function and maintained health-related quality of life in patients with early-stage ATTR-PN and the Val30Met mutation. TTR tetramers were stabilized in nearly all patients, and nutritional status was generally maintained or improved. Similar benefit was seen with tafamidis over 12 months in a noncomparative trial in patients with non-Val30Met ATTR-PN, although disease progression in this population (which was older and had had ATTR-PN for longer than Val30Met patients) became more notable with continued therapy in an extension study. Data for up to 10 years from large registry and referral centre studies support the long-term effectiveness and safety of tafamidis in delaying disease progression and conferring survival benefits in patients with stage 1 ATTR-PN. Tafamidis was generally well tolerated, with no new safety signals detected during the long-term trial or real-world experience. Thus, based on up to 10 years’ experience, tafamidis continues to be a valuable option in the treatment of early-stage ATTR-PN.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

(adapted from Scott [11])

Similar content being viewed by others

References

  1. Ando Y, Coelho T, Berk JL, et al. Guideline of transthyretin-related hereditary amyloidosis for clinicians. Orphanet J Rare Dis. 2013;8:31.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Hou X, Aguilar M-I, Small DH. Transthyretin and familial amyloidotic polyneuropathy: recent progress in understanding the molecular mechanism of neurodegeneration. FEBS J. 2007;274(7):1637–50.

    Article  CAS  PubMed  Google Scholar 

  3. Sekijima Y, Ueda M, Koike H, et al. Diagnosis and management of transthyretin familial amyloid polyneuropathy in Japan: red-flag symptom clusters and treatment algorithm. Orphanet J Rare Dis. 2018;13(1):6.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Schmidt HH, Waddington-Cruz M, Botteman MF, et al. Estimating the global prevalence of transthyretin familial amyloid polyneuropathy. Muscle Nerve. 2018;57(5):829–37.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Adams D, Suhr OB, Hund E, et al. First European consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy. Curr Opin Neurol. 2016;29(Suppl 1):S14–26.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Hawkins PN, Ando Y, Dispenzeri A, et al. Evolving landscape in the management of transthyretin amyloidosis. Ann Med. 2015;47(8):625–38.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Ericzon BG, Wilczek HE, Larsson M, et al. Liver transplantation for hereditary transthyretin amyloidosis: after 20 years still the best therapeutic alternative? Transplantation. 2015;99(9):1847–54.

    Article  CAS  PubMed  Google Scholar 

  8. Sekijima Y. Recent progress in the understanding and treatment of transthyretin amyloidosis. J Clin Pharm Ther. 2014;39(3):225–33.

    Article  CAS  PubMed  Google Scholar 

  9. Plante-Bordenave V. Transthyretin familial amyloid polyneuropathy: an update. J Neurol. 2018;265:976–83.

    Article  CAS  Google Scholar 

  10. Coelho T, Merlini G, Bulawa CE, et al. Mechanism of action and clinical application of tafamidis in hereditary transthyretin amyloidosis. Neurol Ther. 2016;5(1):1–25.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Scott LJ. Tafamidis: a review of its use in familial amyloid polyneuropathy. Drugs. 2014;74(12):1371–8.

    Article  CAS  PubMed  Google Scholar 

  12. Bulawa CE, Connelly S, DeVit M, et al. Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade. Proc Natl Acad Sci USA. 2012;109(24):9629–34.

    Article  PubMed  Google Scholar 

  13. European Medicines Agency. Vyndaqel (tafamidis) 20 mg soft capsules: summary of product characteristics. 2016. http://www.ema.europa.eu/. Accessed 2 May 2019.

  14. Coelho T, Maia LF, Martins da Silva A, et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology. 2012;79(8):785–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Coelho T, Maia LF, Martins da Silva A, et al. Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy. J Neurol. 2013;260(11):2802–14.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Barroso FA, Judge DP, Ebede B, et al. Long-term safety and efficacy of tafamidis for the treatment of hereditary transthyretin amyloid polyneuropathy: results up to 6 years. Amyloid. 2017;24(3):194–204.

    Article  CAS  PubMed  Google Scholar 

  17. Ando Y, Sekijima Y, Obayashi K, et al. Effects of tafamidis treatment on transthyretin (TTR) stabilization, efficacy, and safety in Japanese patients with familial amyloid polyneuropathy (TTR-FAP) with Val30Met and non-Val30Met: a phase III, open-label study. J Neurol Sci. 2016;362:266–71.

    Article  CAS  PubMed  Google Scholar 

  18. Merlini G, Planté-Bordeneuve V, Judge DP, et al. Effects of tafamidis on transthyretin stabilization and clinical outcomes in patients with non-Val30Met transthyretin amyloidosis. J Cardiovasc Transl Res. 2013;6(6):1011–20.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Amass L, Li H, Gundapaneni B, et al. Influence of baseline neurologic severity on disease progression and the associated disease-modifying effects of tafamidis in patients with transthyretin amyloid polyneuropathy. Orphanet J Rare Dis. 2018;13:225.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Gundapaneni BK, Sultan MB, Keohane DJ, et al. Tafamidis delays neurological progression comparably across Val30Met and non-Val30Met genotypes in transthyretin familial amyloid polyneuropathy. Eur J Neurol. 2018;25(3):464–8.

    Article  CAS  PubMed  Google Scholar 

  21. Keohane D, Schwartz J, Gundapaneni B, et al. Tafamidis delays disease progression in patients with early stage transthyretin familial amyloid polyneuropathy: additional supportive analyses from the pivotal trial. Amyloid. 2017;24(1):30–6.

    Article  CAS  PubMed  Google Scholar 

  22. Waddington Cruz M, Amass L, Keohane D, et al. Early intervention with tafamidis provides long-term (5.5-year) delay of neurologic progression in transthyretin hereditary amyloid polyneuropathy. Amyloid. 2016;23(3):178–83.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Coelho T, Inês M, Conceição I, et al. Natural history and survival in stage I Val30Met transthyretin familial amyloid polyneuropathy. Neurology. 2018;91(21):e1999–2009.

    Article  CAS  PubMed  Google Scholar 

  24. Cortese A, Vita G, Luigetti M, et al. Monitoring effectiveness and safety of tafamidis in transthyretin amyloidosis in Italy: a longitudinal multicenter study in a non-endemic area. J Neurol. 2016;263(5):916–24.

    Article  CAS  PubMed  Google Scholar 

  25. Mundayat R, Stewart M, Alvir J, et al. Positive effectiveness of tafamidis in delaying disease progression in transthyretin familial amyloid polyneuropathy up to 2 years: an analysis from the Transthyretin Amyloidosis Outcomes Survey (THAOS). Neurol Ther. 2018;7(1):87–101.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Plante-Bordeneuve V, Gorram F, Salhi H, et al. Long-term treatment of transthyretin familial amyloid polyneuropathy with tafamidis: a clinical and neurophysiological study. J Neurol. 2017;264(2):268–76.

    Article  CAS  PubMed  Google Scholar 

  27. Sousa S, Valdrez K, Fonseca I, et al. Prediction of nerve conduction studies outcomes in patients with familial amyloidotic polyneuropathy receiving tafamidis therapy. J Neuromuscul Dis. 2016;3(Suppl 1):S77–8.

    Google Scholar 

  28. European Medicines Agency. Tafamidis: CHMP assessment report. 2011. http://www.ema.europa.eu/. Accessed 2 May 2019.

  29. Damy T, Judge DP, Kristen AV, et al. Cardiac findings and events observed in an open-label clinical trial of tafamidis in patients with non-Val30Met and non-Val122Ile hereditary transthyretin amyloidosis. J Cardiovasc Transl Res. 2015;8(2):117–27.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Pfizer Inc. Vyndaqel® capsules 20 mg: Japanese prescribing information. 2016. http://www.pmda.go.jp/. Accessed 2 May 2019.

  31. McKeage K, Lyseng-Williamson KA, Scott LJ. Tafamidis in transthyretin amyloidosis: a guide to its use in delaying peripheral neurological impairment in patients with stage 1 polyneuropathy. Drug Ther Perspect. 2017;33(2):47–53.

    Article  Google Scholar 

  32. Pinto MV, Barreira AA, Bulle AS, et al. Brazilian consensus for diagnosis, management and treatment of transthyretin familial amyloid polyneuropathy. Arq Neuropsiquiatr. 2018;76(9):609–21.

    Article  PubMed  Google Scholar 

  33. Keam SJ. Inotersen: first global approval. Drugs. 2018;78:1–6.

    Article  CAS  Google Scholar 

  34. Hoy S. Patisiran: first global approval. Drugs. 2018;78:1625–31.

    Article  CAS  PubMed  Google Scholar 

  35. Alnylam Pharmaceuticals Inc. ONPATTRO (patisiran) lipid complex injection, for intravenous use. 2018. http://www.alnylam.com/. Accessed 2 May 2019.

  36. Ionis Pharmaceuticals Inc. TEGSEDI (inotersen) injection, for subcutaneous use. 2018. http://tegsedi.com/. Accessed 2 May 2019.

  37. Adams D, Théaudin M, Cauquil C, et al. FAP neuropathy and emerging treatments. Curr Neurol Neurosci Rep. 2014;14(3):435.

    Article  CAS  PubMed  Google Scholar 

  38. Mariani L-L, Lozeron P, Théaudin M, et al. Genotype-phenotype correlation and course of transthyretin familial amyoid polyneuropathies in France. Ann Neurol. 2015;78(6):901–16.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Lozeron P, Theaudin M, Mincheva Z, et al. Effect on disability and safety of tafamidis in late onset of Met30 transthyretin familial amyloid polyneuropathy. Eur J Neurol. 2013;20(12):1539–45.

    Article  CAS  PubMed  Google Scholar 

  40. Maurer MS, Schwartz JH, Gundapaneni B, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med. 2018;27:1007–16.

    Article  Google Scholar 

  41. Vita G, Vita GL, Stancanelli C, et al. Genetic neuromuscular disorders: living the era of a therapeutic revolution. Part 1: peripheral neuropathies. Neurol Sci. 2019;40(4):661–9.

    Article  PubMed  Google Scholar 

  42. Plante-Bordeneuve V, Lin H, Gollob J, et al. An indirect treatment comparison of the efficacy of patisiran and tafamidis for the treatment of hereditary transthyretin-mediated amyloidosis with polyneuropathy. Expert Opin Pharmacother. 2018;20(4):473–81.

    Article  CAS  PubMed  Google Scholar 

  43. Klamerus KJ, Watsky E, Moller R, et al. The effect of tafamidis on the QTc interval in healthy subjects. Br J Clin Pharmacol. 2015;79(6):918–25.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Suhr OB, Conceicao IM, Karayal ON, et al. Post hoc analysis of nutritional status in patients with transthyretin familial amyloid polyneuropathy: impact of tafamidis. Neurol Ther. 2014;3(2):101–12.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

During the peer review process, the manufacturer of tafamidis was also offered an opportunity to review this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.

Author information

Authors and Affiliations

  1. Springer, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand

    Yvette N. Lamb & Emma D. Deeks

Authors
  1. Yvette N. Lamb
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Emma D. Deeks
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yvette N. Lamb.

Ethics declarations

Funding

The preparation of this review was not supported by any external funding.

Conflict of interest

Yvette Lamb and Emma Deeks are salaried employees of Adis/Springer, responsible for the article content and declare no relevant conflicts of interest.

Additional information

The manuscript was reviewed by:F. Barroso, Department of Neurology, Institute for Neurological Research Raul Carrea (FLENI), Buenos Aires, Argentina; M. Waddington Cruz, National Amyloidosis Referral Center (CEPARM), University Hospital, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lamb, Y.N., Deeks, E.D. Tafamidis: A Review in Transthyretin Amyloidosis with Polyneuropathy. Drugs 79, 863–874 (2019). https://doi.org/10.1007/s40265-019-01129-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40265-019-01129-6

Search

Navigation